Neuropharmacology & Psychopharmacology | Methods for Diagnostic & Therapeutic Studies | Multiple Sclerosis & Related Disorders
Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in the Netherlands
22nd Meeting of the European Neurological Society 2012, 9 - 12 Jun 2012, P343
The objective of the conducted cost-minimization analysis was to assess the costs of oral treatment with Gilenya® (fingolimod) compared to intravenous infusion of Tysabri® (natalizumab) in patients with relapsing-remitting multiple sclerosis (RRMS) in the Netherlands.
The opinion of the scientific advisory group of the European Medicines Agency (EMA) and the fact that the registered indications for fingolimod and natalizumab are equal in the European Union formed the basis for the cost-minimization approach undertaken in this study. Under the condition of similar efficacy and tolerability, the presented analyses showed that treatment with fingolimod was estimated to result in substantial as well as robust costs savings compared to treatment with natalizumab in patients with relapsing-remitting multiple sclerosis in the Netherlands.
Post-marketing data may provide new insights in the (near) future, but are currently too scarce to reject/reinforce comparability between fingolimod and natalizumab based on the placebo-controlled trials FREEDOMS (1) and AFFIRM (2).
Corresponding authors WS van der Hel and coauthor MT Groot are paid employees of Novartis Pharma B.V. Coauthors M Heisen, MJ Treur and BG Verheggen are paid employees of Pharmerit B.V., a consulting company which provides services to Novartis Pharma B.V. amongst others.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License